Serum Progranulin Concentrations May Be Associated With Macrophage Infiltration Into Omental Adipose Tissue by Youn, Byung-Soo et al.
Serum Progranulin Concentrations May Be Associated
With Macrophage Inﬁltration Into Omental Adipose
Tissue
Byung-Soo Youn,
1 Sa-Ik Bang,
2 Nora Klo ¨ting,
3 Ji Woo Park,
1 Namseok Lee,
1 Ji-Eun Oh,
1
Kyung-Bae Pi,
1 Tae Hee Lee,
4 Karen Ruschke,
3 Mathias Fasshauer,
3 Michael Stumvoll,
3
and Matthias Blu ¨her
3
OBJECTIVE—Progranulin is an important molecule in inﬂam-
matory response. Chronic inﬂammation is frequently associated
with central obesity and associated disturbances; however, the
role of circulating progranulin in human obesity, type 2 diabetes,
and dyslipidemia is unknown.
RESEARCH DESIGN AND METHODS—For the measurement
of progranulin serum concentrations, we developed an enzyme-
linked immunosorbent assay (ELISA). Using this ELISA, we
assessed circulating progranulin in a cross-sectional study of 209
subjects with a wide range of obesity, body fat distribution,
insulin sensitivity, and glucose tolerance and in 60 individuals
with normal (NGT) or impaired (IGT) glucose tolerance or type
2 diabetes before and after a 4-week physical training program.
Progranulin mRNA and protein expression was measured in
paired samples of omental and subcutaneous adipose tissue
(adipocytes and cells of the stromal vascular fraction) from 55
lean or obese individuals. Measurement of Erk activation and
chemotactic activity induced by progranulin in vitro was per-
formed using THP-1–based cell migration assays.
RESULTS—Progranulin serum concentrations were signiﬁ-
cantly higher in individuals with type 2 diabetes compared with
NGT and in obese subjects with predominant visceral fat accu-
mulation. Circulating progranulin signiﬁcantly correlates with
BMI, macrophage inﬁltration in omental adipose tissue, C-reac-
tive protein (CRP) serum concentrations, A1C values, and total
cholesterol. Multivariable linear regression analyses revealed
CRP levels as the strongest independent predictor of circulating
progranulin. The extent of in vitro progranulin-mediated chemo-
taxis is similar to that of monocyte chemoattractant protein-1 but
independent of G. Moreover, in type 2 diabetes, but not in IGT
and NGT individuals, physical training for 4 weeks resulted in
signiﬁcantly decreased circulating progranulin levels.
CONCLUSIONS—Elevated progranulin serum concentrations
are associated with visceral obesity, elevated plasma glucose,
and dyslipidemia. We identiﬁed progranulin as a novel marker of
chronic inﬂammation in obesity and type 2 diabetes that closely
reﬂects omental adipose tissue macrophage inﬁltration. Physical
training signiﬁcantly reduces elevated circulating progranulin in
patients with type 2 diabetes. Diabetes 58:627–636, 2009
I
mmune response and metabolic regulation are
highly integrated, and the proper function of each is
dependent on the other (1). Chronic inﬂammation is
frequently associated with central obesity and asso-
ciated disturbances (2). In patients with obesity and type 2
diabetes, altered serum concentrations of inﬂammatory
markers, including high-sensitivity C-reactive protein, tu-
mor necrosis factor- (TNF-), ﬁbrinogen, interleukin
(IL)-10, adiponectin, and IL-6, have been frequently re-
ported (2–5). However, the link between inﬂammation and
central obesity is not fully understood.
Progranulin is a secreted protein with important func-
tions in several processes, including immune response and
embryonic development (6). Progranulin, also known as
granulin, acrogranin, proepithelin, and PC cell–derived
growth factor, is a 593–amino acid glycoprotein, the
mRNA of which is expressed in many epithelial cells both
in vitro and in vivo. The widespread occurrence of pro-
granulin mRNA in cells from the hematopoietic system
and in epithelia implies important functions in these
tissues. Autosomal dominant mutations in the progranulin
gene cause frontotemporal dementia (7,8), whereas over-
expression of progranulin promotes the invasive progres-
sion of a range of tumors, including those of the breast and
the brain (9). It has been shown that overexpression of
progranulin renders breast cancer cells resistant to tamox-
ifen (10), suggesting that autocrine regulation of progranu-
lin by cancer cells is critically involved in breast cancer
tumorigenesis (11). It was also found that in murine
transcutaneous puncture wounds, progranulin mRNA is
expressed in the inﬂammatory inﬁltrate and is highly
induced in dermal ﬁbroblasts and endothelia after injury
(12). When applied to a cutaneous wound, progranulin
increased the accumulation of neutrophils, macrophages,
blood vessels, and ﬁbroblasts in the wound (13), suggest-
ing that progranulin could function as a chemotactic
protein for myeloid-origin cell types and an angiogenic
factor. A recent study showed that progranulin is an
inducible protein in response to hypoxia or acidosis (14).
Taken together, progranulin is an important molecule in
inﬂammatory response and could therefore be involved in
chronic subclinical inﬂammation associated with human
obesity and type 2 diabetes. However, the role of circulat-
ing progranulin in human central obesity and its associ-
ated comorbidities is unknown. We therefore developed
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DIABETES, VOL. 58, MARCH 2009 627an enzyme-linked immunosorbent assay (ELISA) for the
measurement of human progranulin serum concentra-
tions. To this end, a human progranulin-speciﬁc polyclonal
antibody (PAb) was generated, which was then used to
create a sandwich ELISA. Using this new progranulin
ELISA, we sought to determine circulating progranulin in
individuals with a wide range of obesity, body fat distri-
bution, insulin sensitivity, and glucose tolerance. In addi-
tion, we assessed progranulin serum concentration before
and after an intensive 4-week physical training program to
test whether progranulin levels are regulated in response
to training-associated improvements in body weight and
insulin sensitivity. Adipose tissue has gained recognition
as an important contributor to chronic systemic inﬂamma-
tion (15–17). Especially omental macrophage inﬁltration
correlates with measures of central obesity and associated
disturbances (17,18). Different adipokines, including
monocyte chemoattractant protein-1 (MCP-1), have been
shown to recruit monocytes into adipose tissue (19). We
therefore tested the hypothesis that progranulin could
facilitate monocyte recruitment into adipose tissue and
that circulating progranulin reﬂects macrophage inﬁltra-
tion into omental adipose tissue.
RESEARCH DESIGN AND METHODS
We included three different cohorts with a total number of 269 individuals in
our study of progranulin serum concentration, adipose tissue mRNA, and
protein expression. In the ﬁrst cohort (n  154), we investigated progranulin
serum concentrations in relation to measures of obesity and glucose metab-
olism in a cross-sectional study (cohort 1). In another cross-sectional study
(cohort 2), we investigated progranulin mRNA and protein expression in
paired omental and subcutaneous adipose tissue samples in addition to
progranulin serum concentrations (n  55). In a third study (cohort 3), we
investigated circulating progranulin in response to a 4-week intensive exercise
intervention in 60 individuals with different degrees of glucose tolerance.
Individuals of all three cohorts fulﬁlled the following inclusion criteria: 1)
Absence of any acute or chronic inﬂammatory disease as determined by a
leukocyte count 7,000 Gpt/l, C-reactive protein (CRP) 5.0 mg/dl, or clinical
signs of infection; 2) undetectable antibodies against glutamic acid decarbox-
ylase; 3) no medical history of hypertension, i.e., systolic blood pressure was
140 mmHg and diastolic blood pressure was 85 mmHg; 4) no clinical
evidence of either cardiovascular or peripheral artery disease; 5) no thyroid
dysfunction; 6) no alcohol or drug abuse; and 7) no pregnancy. All study
protocols have been approved by the ethics committee of the University of
Leipzig. All participants gave written informed consent before taking part in
the study. The three cohorts had the following speciﬁc characteristics.
Cohort 1. A total of 154 Caucasian men (n  60) and women (n  98) have
been consecutively recruited in the context of a study on insulin resistance at
the Department of Medicine, University of Leipzig, to represent a wide range
of obesity, insulin sensitivity, and glucose tolerance. The age ranged from 25
to 79 years and BMI from 20.2 to 61.5 kg/m
2. The study included 124 patients
with type 2 diabetes and 30 normal glucose tolerant (NGT) control subjects
(Table 1).
Cohort 2. Adipose tissue progranulin mRNA and protein expression was
investigated in 55 previously described donors of paired omental and subcu-
taneous adipose tissue samples (20), who underwent open abdominal surgery
for cholecystectomy, weight reduction surgery, abdominal injuries, or explor-
ative laparotomy. All subjects had a stable weight, deﬁned as the absence of
ﬂuctuations of 2% of body weight for at least 3 months before surgery.
Adipose tissue was either analyzed as a whole (immediately frozen in liquid
nitrogen after explantation) or after separation into isolated adipocytes and
cells of the stromal vascular fraction (SVF) using previously described
methods (21). Histological analyses and measurement of macrophage count in
adipose tissue was performed as previously described (18). In brief, adipose
tissue samples were ﬁxed at room temperature in 4% formaldehyde and
embedded in parafﬁn. Five-micrometer sections were mounted on glass slides,
deparafﬁnized in xylol, and stained for CD68 using anti-CD68 monoclonal
mouse antihuman antibody (close PGM1 M0876, dilution 1:100; Dako,
Glostrup, Denmark) or stained for human progranulin using the novel
developed human polyclonal anti-progranulin antibody (AG 101; AdipoGen,
Seoul, Korea) with standard immunostaining methods. Macrophages were
identiﬁed in the adipose parenchyma when cytoplasmic staining for CD68 was
present along with an identiﬁable mononuclear nucleus and presented as the
number per 100 adipocytes (percent macrophages).
Cohort 3. Sixty subjects were divided into groups of NGT (n  20; 9 men, 11
women), impaired glucose tolerance (IGT, n  20; 9 men, 11 women), and
type 2 diabetes (n  20; 11 men, 9 women) on the basis of a 75-g oral glucose
tolerance test (OGTT) according to the American Diabetes Association
criteria (22). Subjects with NGT were deﬁned by a fasting plasma glucose 6.0
mmol/l and a 120-min plasma glucose 7.8 mmol/l. Subjects with IGT were
deﬁned by a fasting plasma glucose 6.0 mmol/l, a 120-min plasma glucose
7.8 mmol/l and 11.1 mmol/l. Subjects with type 2 diabetes were deﬁned by
a fasting plasma glucose 7.0 mmol/l and/or a 120-min OGTT glucose 11.1
mmol/l.
These 60 individuals were enrolled in 60 min of supervised physical
training sessions 3 days per week as described previously (4). In brief, each
training session included 20 min of biking or running, 20 min of swimming,
and 20 min of warming up/cooling down periods. All subjects completed a
graded bicycle-ergometer test to volitional exhaustion and had maximal
oxygen uptake (Vo2max) measured with an automated open circuit gas analysis
system at baseline and after 4 weeks of training. The highest oxygen
uptake/min reached was deﬁned as the Vo2max, and subjects subsequently
TABLE 1
Anthropometric and metabolic characteristics of the study groups
Normal glucose tolerant Type 2 diabetes
Men Women Men Women
n 12 18 48 76
Age (years) 61  12 56  15 62  76 2  8
Body weight (kg) 91  20* 89  23 103  17† 90  17
BMI (kg/m
2) 29  3*† 33  43 5  6* 33  7
Body fat (%) 22  1*† 41  83 0  5† 41  6
A1C (%) 5.5  1.8* 5.4  0.7* 6.6  1.0 6.6  1.0
Fasting plasma glucose (mmol/l) 5.3  1.2* 5.2  0.6* 7.5  2.2 7.2  2.0
Fasting plasma insulin (pmol/l) 38  12*† 58  11* 136  253 145  116
Free fatty acids (mmol/l) 0.45  0.48* 0.48  0.27* 0.66  0.25 0.62  0.26
Cholesterol (mmol/l) 4.3  0.6*† 5.2  0.8 5.0  1.0 5.5  1.1
HDL cholesterol (mmol/l) 1.3  0.2*† 1.6  0.2* 1.1  0.2† 1.4  0.3
LDL cholesterol (mmol/l) 2.7  0.6*† 3.4  0.3* 3.3  1.0† 3.7  0.9
Triglycerides (mmol/l) 1.4  0.6* 1.5  0.8* 2.0  0.7 2.0  1.2
Leptin 9.7  7.7*† 25.3  16.9 14.8  11.0† 28.8  18.9
Adiponectin 5.5  2.3*† 8.6  3.8 3.7  2.4 6.5  3.2
hsCRP (mg/dl) 0.22  0.1* 0.29  0.1* 0.34  0.27† 0.45  0.36
Data are means  SD. *P  0.05 for patients with type 2 diabetes versus normal glucose tolerant individuals within each sex. †P  0.05 for
difference between men and women within the normal glucose tolerant or type 2 diabetes group.
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individual maximal heart rate during the bicycle-ergometer test. At baseline
and after 4 weeks of training (48 h after the last training session), blood
samples were obtained in the fasting state and measurements of anthropo-
metric parameters were performed. We further assessed circulating progranu-
lin before, immediately after, and after 24 and 48 h of an acute exercise circle
training to exhaustion for 60 min in 20 healthy volunteers.
Measurement of body fat content, glucose metabolism, and insulin
sensitivity. All baseline blood samples were collected between 8:00 and 10:00
A.M. after an overnight fast. Plasma insulin was measured with an enzyme
immunometric assay for the IMMULITE automated analyzer (Diagnostic
Products, Los Angeles, CA). Serum high-sensitive CRP was measured by
immunonephelometry (Dade-Behring, Milan, Italy). Serum adiponectin and
IL-6 were measured as previously described (4). Serum MCP-1 concentrations
were measured by immunoassay system (Quantikine human MCP-1 Immuno-
assay; R&D Systems, Minneapolis, MN). BMI was calculated as weight divided
by squared height. Hip circumference was measured over the buttocks; waist
circumference was measured at the midpoint between the lower ribs and iliac
crest. Percentage body fat was measured by dual X-ray absorptiometry. In
addition, abdominal visceral and subcutaneous fat areas were calculated
using computed tomography (CT) scans at the level of L4–L5 in the cohort of
paired visceral and subcutaneous adipose tissue donors. Based on a previous
report (23), visceral obesity was deﬁned as 0.4 ratio of visceral to subcuta-
neous fat area as determined by CT scan. Three days before the OGTT,
patients documented a high-carbohydrate diet in diet protocols. The OGTT
was performed after an overnight fast with 75-g standardized glucose solution
(Glucodex Solution 75 g; Merieux, Montreal, Canada). Venous blood samples
were taken at 0, 60, and 120 min for measurements of plasma glucose
concentrations. Insulin sensitivity was assessed with the euglycemic-hyperin-
sulinemic clamp method (24,25).
Progranulin ELISA development and measurement of progranulin
serum concentrations. A cDNA sequence encoding the original signal
peptide sequence and the mature peptide of human progranulin was ampliﬁed
and digested with appropriate restriction enzymes and then cloned into both
pAGCF (AdipoGen, Seoul, Korea). A FLAG tag was incorporated at the mature
human progranulin peptide. pAGCF is an in-house eukaryotic vector whose
expression is driven by the cytomegalovirus early promoter. The tagged
protein was expressed in a human embryonic kidney cell line, HEK-293, and
puriﬁed from conditioned media through anti-FLAG Sepharose column.
Endotoxin was removed through two consecutive column chromatography
using Detoxigel (Pierce, Rockford, IL). PAb (AG 101) was then produced by
immunizing with recombinant FLAG-tagged human progranulin according to
general protocols. Immunoglobulin fractions were prepared from serum and
then biotinylated. FLAG-tagged progranulin was used for ELISA standard at a
variety of dilutions. A sandwich ELISA format was designed with the use of a
pair of PAb and biotinylated PAb. A total of 100 l of the human serum in 1:200
dilutions was applied to each well, which has been coated by 5 g/ml human
progranulin–speciﬁc PAb and was incubated at 37°C for 1 h followed by
washing three times with PBS with 0.05% Tween-20 (PBST). Per well, 100 l
biotinylated PAb at 5 mg/ml was added. The secondary antibody reaction was
performed at 37°C for 1 h followed by washing three times with PBST.
Colorimetric reaction was conducted for 20 min with the use of horseradish
peroxidase–conjugated streptavidin (Zymed, South San Francisco, CA) di-
luted 1:1,000 in PBS and 2,2-azino-bis(2-ethylbenzothiazoline-6-sulfonic acid)
(Pierce) as substrate. The optical density was measured at 450 nm. Its
sensitivity was 32 pg/ml. Whereas the degree of precision of the ELISA system
in terms of coefﬁcient of variance (%) of intra-assay was between 3 and 6.9%
(supplementary Table 1, available in an online appendix at http://dx.doi.org/
10.2337/db08-1147), that of interassays was between 4.7 and 7.3% (supplemen-
tary Table 2, available in the online appendix). Spike recovery (supplementary
Table 3, available in the online appendix) and linearity (supplementary Table
4, available in the online appendix) were in a range of 89–103 and 93–102%,
respectively. Speciﬁcity was determined using human adiponectin, retinol
binding protein 4, visfatin, leptin, plasminogen activator inhibitor-1 (PAI-1),
TNF-, resistin-like molecule-, fatty acid binding protein 4, angiopoietin-like
protein 3 (ANGPTL3), ANGPTL6, glutathione peroxidase 3, clusterin, resistin,
mouse visfatin, rat visfatin, and mouse resistin (supplementary Table 5,
available in the online appendix).
Progranulin mRNA and protein expression. Human progranulin mRNA
expression was measured by quantitative real-time RT-PCR in a ﬂuorescent
temperature cycler using the TaqMan assay, and ﬂuorescence was detected on
an ABI PRISM 7000 sequence detector (Applied Biosystems, Darmstadt,
Germany). Total RNA was isolated from paired subcutaneous and visceral
adipose tissue samples using TRIzol (Life Technologies, Grand Island, NY),
and 1 g RNA was reverse transcribed with standard reagents (Life Technol-
ogies). From each RT-PCR, 2 l was ampliﬁed in a 26-l PCR using the
Brilliant SYBR Green QPCR Core Reagent kit from Stratagene (La Jolla, CA)
according to the manufacturer’s instructions. Samples were incubated in the
ABI PRISM 7000 sequence detector for an initial denaturation at 95°C for 10
min, followed by 40 PCR cycles, each cycle consisting of 95°C for 15 s, 60°C
for 1 min, and 72°C for 1 min. The following primers were used: human
progranulin, 5-gaaggctcgatcctgcgaga-3 (sense) and 5-ctcaaggctgggtccctcaa-3
(antisense). SYBR Green I ﬂuorescence emissions were monitored after each
cycle. Human progranulin mRNA expression was calculated relative to the
mRNA expression of 18S rRNA, determined by a premixed assay on demand
for human 18S rRNA (PE Biosystems). Ampliﬁcation of speciﬁc transcripts
was conﬁrmed by melting curve proﬁles (cooling the sample to 68°C and
heating slowly to 95°C with measurement of ﬂuorescence) at the end of each
PCR. The speciﬁcity of the PCR was further veriﬁed by subjecting the
ampliﬁcation products to agarose gel electrophoresis. Progranulin protein
expression in visceral and subcutaneous adipose tissue and in isolated
adipocytes and SVF was measured in a representative subgroup of 30 subjects
by Western blot analysis using the novel generated human progranulin-
speciﬁc PAb (AG 101). Three blots of the samples were scanned using a
Molecular Dynamics Storm PhosphoImager and quantiﬁed with ImageQuant
software.
Detection of Erk activation in cells treated with recombinant human
progranulin. To examine the signals of phospho-p44/42 mitogen-activated
protein kinase (MAPK) and p44/42 MAPK, MCF10A, a human breast epithelial
cell line, and THP-1, a human monocytic leukemic cell line, were serum-
starved for 24 h and treated with 500 ng/ml or 100 ng/ml recombinant human
progranulin, respectively. Cell lysates were prepared with radioimmunopre-
cipitation assay buffer. Equal amounts of protein were subjected to Western
blot analyses with phosphorylation-speciﬁc Erk and pan-Erk antibodies (Cell
Signaling Technology, Danvers, MA).
Measurement of chemotactic activity of human progranulin using
THP-1 cells. Cell migration of THP-1 monocytic leukemia cells was carried
out in 24-well transwell polystyrene membrane with 8-m pore size. 2 	 10
5
THP-1 cells were added to the upper chamber. A total of 100 ng/ml hProgranu-
lin-FLAG was diluted in RPMI 1640 supplemented with 0.5% fetal bovine
serum (FBS) and was then added to the low chamber. Together with THP-1
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FIG. 1. Progranulin serum concentrations in NGT individuals and patients with type 2 diabetes (T2D). Circulating progranulin in men (n  12)
and women (n  18) with NGT (A) and in individuals with either type 2 diabetes (n  124) or NGT (n  30) (B). Data are means  SE.
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5 cells per well), 0, 10, 50, 100, and 250 ng/ml hProgranulin were
added into the upper chamber. As a control, human progranulin was boiled for
10 min. After 16-h incubation at 37°C in a 5% CO2 humidiﬁed atmosphere,
migrated cells in the lower chamber were counted. Migrated cells in two
separate ﬁelds per well from duplicate wells were enumerated on a hemacy-
tometer by means of light microscopy. For a modiﬁed checkerboard analysis,
100 ng/ml human progranulin was placed into the low chamber, and a mixture
of 2 	 10
5 THP-1 cells and varied concentrations of human progranulin (0, 10,
50, 100, and 250 ng/ml) was added into upper chambers. As control, human
MCP-1 was used for chemotaxis experiments. For inhibitory chemotaxis
assays, THP-1 cells were pretreated at 37°C for 1 h with 1 g/ml pertussis
toxin (PTX) or 20 mol/l PD98059, washed, and placed into upper chambers.
Statistical analyses. Data are shown as means  SE unless stated otherwise.
Before statistical analysis, non-normally distributed parameters were logarithmi-
cally transformed to approximate a normal distribution. The following statistical
tests were used: paired Student’s t test, 
 quadrate test, and Pearson’s simple
correlation. Linear relationships were assessed by least square regression analy-
sis. Statistical analysis was performed using SPSS version 12.0 (Chicago, IL). P
values 0.05 were considered to be statistically signiﬁcant.
RESULTS
Progranulin serum concentrations in obesity and
type 2 diabetes. Anthropometric and metabolic charac-
teristics of 154 individuals in the ﬁrst cross-sectional study
are summarized in Table 1. The current ELISA system was
made possible by human progranulin-speciﬁc PAb. No
cross-reactivity was observed with the use of a number of
classical or new adipokines (supplementary Table 5). The
progranulin ELISA ran according to the supplementary
methods (supplementary tables, available in the online
appendix). Circulating progranulin was not different be-
tween men and women with NGT (Fig. 1A) and type 2
diabetes (data not shown). Progranulin levels were 1.4-
fold higher in individuals with type 2 diabetes compared
with NGT (Fig. 1B)( P  0.007). In these patients with a
wide range of BMI and glucose tolerance, we found
signiﬁcant relationships between circulating progranulin
and parameters of central obesity and its associated
comorbidities. Univariate regression analyses revealed sig-
niﬁcant correlations between progranulin serum concen-
trations and A1C, CRP serum concentrations, BMI, and
total cholesterol serum concentrations (Fig. 2). There was
no correlation between serum progranulin concentration
and circulating IL-6 (r  0.08, P  0.7) and adiponectin
(r  0.14, P  0.3), whereas circulating progranulin and
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FIG. 2. Relationship between progranulin serum concentrations and anthropometric and metabolic parameters. Correlation between circulating
progranulin and A1C (r
2  0.25, P < 0.01) (A), circulating CRP (r
2  0.4, P < 0.001) (B), BMI (r
2  0.2, P < 0.05) (C), and total cholesterol serum
concentration (r
2  0.2, P < 0.05) (D). Data are log transformed to achieve normal distribution. hsCRP, high-sensitivity C-reactive protein.
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variable linear regression models revealed that circulating
CRP is the strongest predictor of progranulin serum con-
centration (Table 2). Associations between circulating
progranulin and BMI or A1C are not independent of the
signiﬁcant relationship between circulating progranulin
and CRP (Table 2).
Circulating progranulin correlates with macrophage
inﬁltration into adipose tissue. We investigated pro-
granulin mRNA and protein expression in visceral and
subcutaneous adipose tissue in parallel with progranulin
serum concentrations in a group of lean and obese indi-
viduals, which have been classiﬁed into lean or predomi-
nantly subcutaneously or viscerally obese on the basis of
abdominal visceral and subcutaneous fat area measure-
ments using CT scans at the level of L4–L5 as previously
described (23,25). Progranulin levels were not signiﬁcantly
different between subcutaneous obese and lean individu-
als, whereas patients with a predominantly visceral fat
distribution had signiﬁcantly higher progranulin serum
levels (P  0.01) (Fig. 3A). There is a signiﬁcant correla-
tion between circulating progranulin and visceral fat area
as measured by CT scan (r  0.42, P  0.001). In this
cohort, we further investigated the relationship between
circulating progranulin and macrophage count in subcuta-
neous and omental adipose tissue. Macrophage number
was signiﬁcantly higher in visceral than in subcutaneous
fat (18). We found a strong correlation between circulating
progranulin and both subcutaneous (r  0.4, P  0.001)
and omental (Fig. 3B) macrophage number in adipose
tissue. These relationships remained signiﬁcant even on
adjustment for age, sex, BMI, total body fat mass, and
circulating CRP. Progranulin mRNA and protein expres-
sion was signiﬁcantly higher in visceral compared with
subcutaneous fat (Fig. 3C and D). We further sought to
dissect the contribution of adipocytes and cells of the SVF
on progranulin expression in adipose tissue. Immunostain-
ing of adipose tissue sections using the new anti-progranu-
lin antibody demonstrates that progranulin protein is
detectable in vessels and cytoplasm of adipocytes and
cells of the SVF (Fig. 3E). Expression analyses revealed
that both isolated adipocytes and cells of the SVF contrib-
ute to progranulin mRNA expression adipose tissue (Fig.
3F). These results have been conﬁrmed at the protein level
(data not shown).
Visceral progranulin mRNA expression signiﬁcantly cor-
relates with circulating progranulin, CRP, and MCP-1;
visceral fat area; BMI; percent body fat; macrophage
number in visceral fat; HDL cholesterol; and glucose
infusion rate during the steady state of an euglycemic-
hyperinsulinemic clamp, whereas subcutaneous progranu-
lin mRNA only correlates with CRP and subcutaneous
macrophage number (Table 3).
Progranulin activates Erk in vitro. Overexpression of
progranulin has been shown to activate stress-activated
kinase Erk gene in different tumor cell types (10) and
progranulin seems to act on myeloid cells (13). However,
its agonistic potential in vitro has not been substantiated.
We therefore tested whether our recombinant human
progranulin may activate Erk in the human breast cancer
cell line MCF10A and in THP-1. As early as after 10 min of
progranulin treatment, we found signiﬁcantly increased
Erk phosphorylation (Fig. 4A and B) with a sustained
increase up to 60 min, conﬁrming that progranulin is an
Erk activator when used as a ligand in vitro.
Progranulin induces chemotactic activity in vitro in a
G-independent and an Erk-dependent manner. Inﬁl-
tration of macrophages into omentum is a hallmark of
human visceral obesity. To investigate the potential causal
role of progranulin on monocyte recruitment into adipose
tissue in more detail, we tested whether progranulin
promotes cell migration in vitro. To test the hypothesis
that progranulin is a monocyte chemoattractant molecule,
THP-1 cell-based migration assays have been performed. A
typical bell-shaped curve cell migration pattern was in-
duced by different concentrations of human recombinant
progranulin with a maximal migration index at a concen-
tration of 100 ng/ml (Fig. 4C). To test whether this
migration pattern is chemotactic or chemokinetic, a mod-
iﬁed checkerboard analysis was performed. A signiﬁcant
decrease in migrated THP-1 cells treated with progranulin
placed in upper chambers strongly suggests progranulin as
a chemotactic factor for human macrophages (Fig. 4D).
We further compared chemotactic activity of progranulin
and MCP-1 using the THP-1 cell-based migration assays. At
concentrations of 100 ng/ml, progranulin and MCP-1 ex-
erted indistinguishable chemotactic activity (Fig. 4E).
THP-1 cells were pretreated with PTX, which uncouples
endogenous G protein  (G) subunits from G-protein–
coupled receptors. These experiments revealed that pro-
granulin-mediated chemotaxis of human macrophage-like
cells is G independent based on the observation that PTX
did not affect cell migration in progranulin-treated cells,
whereas MCP-1–mediated chemotaxis is G dependent
(Fig. 4E). Because progranulin was able to activate Erk in
THP-1 cells, we tested whether pharmacological inhibition
of Erk affects chemotaxis. Inhibition of Erk by the speciﬁc
Erk inhibitor PD98059 signiﬁcantly attenuated the pro-
granulin-mediated chemotaxis, strongly suggesting that
progranulin-mediated chemotaxis is Erk dependent (Fig.
4F).
Circulating progranulin in response to 4 weeks of
intensive exercise training. Sixty Caucasian men and
women completed a 4-week training program and were
studied after being divided into subjects with NGT (n 
20), IGT (n  20), or type 2 diabetes (n  20) as previously
TABLE 2
Multivariable linear regression analysis of different parameters as
predictors of progranulin serum concentration (n  154)
Progranulin serum concentration
-Coefﬁcient P value
Model 1
Age 0.084 0.306
Sex 0.078 0.341
Model 2
Age 0.143 0.076
Sex 0.039 0.624
hsCRP 0.308 <0.0001
Model 3
Age 0.125 0.142
Sex 0.020 0.817
hsCRP 0.294 0.001
A1C 0.144 0.089
Model 4
Age 0.130 0.130
Sex 0.030 0.728
hsCRP 0.261 0.006
A1C 0.145 0.091
BMI 0.082 0.381
Signiﬁcant correlations are shown in bold.
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signiﬁcant improvement in Vo2max in all groups. As deter-
mined by matched paired t test (P  0.05), all subjects had
a signiﬁcant increase in Vo2max after the training period.
Four weeks of physical training resulted in signiﬁcant
decreases in BMI, WHR, and percent body fat in all glucose
tolerance groups, and insulin sensitivity signiﬁcantly im-
proved in the IGT and type 2 diabetes groups (4).
Progranulin serum concentration signiﬁcantly de-
creased by 20% in type 2 diabetic subjects in response to
the 4-week training program (Fig. 5A). There was a signif-
icant correlation between change in progranulin serum
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FIG. 3. Progranulin serum concentrations in visceral obesity. A: Circulating progranulin in lean, visceral obese, and subcutaneous (SC) obese
individuals with NGT. Abdominal visceral and subcutaneous fat areas were calculated using computed tomography (CT) scans at the level of
L4–L5 in the cohort of paired visceral and subcutaneous adipose tissue donors. Visceral obesity was deﬁned as >0.4 ratio of visceral to
subcutaneous fat area as determined by CT scan. Data are means  SE. *P < 0.05 between the groups. B: Correlation between circulating
progranulin and macrophage inﬁltration into omental adipose tissue (r
2  0.5, P < 0.001). Data are log transformed to achieve normal
distribution. Progranulin mRNA (C) and protein (D) expression in visceral and subcutaneous (SC) adipose tissue is shown. A representative
Western blot is shown. E: Parafﬁn section of visceral adipose tissue of a normal glucose control individual. Immunostaining with a polyclonal
anti-progranulin antibody. Arrows indicate progranulin-positive cytosol of adipocytes and cells of the stroma vascular fraction. F: Progranulin
mRNA expression in isolated adipocytes and SVF. AU, arbitrary units. (Please see http://dx.doi.org/10.2337/db08-1147 for a high-quality digital
representation of this ﬁgure.)
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2  0.3, P  0.007)
after the training program in all groups and in the entire
cohort. Multivariable linear regression analysis further
revealed that reduced CRP is a signiﬁcant predictor of
decreased progranulin serum concentration after training.
In 20 healthy volunteers, we found signiﬁcantly increased
progranulin serum concentrations immediately after 60-
min exercise circle training to exhaustion. Elevated pro-
granulin serum concentrations normalized 24 h after the
acute exercise (Fig. 5B).
DISCUSSION
We report here for the ﬁrst time a strong association of
elevated progranulin serum concentrations with type 2
diabetes, visceral fat accumulation, and increased macro-
phage inﬁltration into adipose tissue. Circulating pro-
granulin levels correlate with markers of inﬂammation
(CRP), chronic hyperglycemia (A1C), and predominantly
visceral fat accumulation. Moreover, in an intervention
study, we could demonstrate that elevated progranulin
serum concentrations in patients with type 2 diabetes can
be decreased by physical training.
Chronic inﬂammation and elevated (CRP, IL-6, TNF-,
and ﬁbrinogen among others) or decreased (adiponectin,
IL-10, and others) inﬂammatory markers are frequently
associated with central obesity and associated distur-
bances (2–5). Increased amount of adipose tissue could
contribute to altered serum proﬁles of inﬂammatory mark-
ers. Visceral fat depot-speciﬁc secretion of adipokines and
immune cell–derived cytokines may at least in part ex-
plain the frequently reported association between central
obesity and chronic inﬂammation (5,26,27). In this con-
text, progranulin caught our attention, because it is a
secreted protein with important functions in modulation
of inﬂammatory events. In addition, the role of progranulin
in obesity and type 2 diabetes has not been investigated.
Progranulin is a multifunctional protein that has gained
attention in the neuroscience ﬁeld, because of the discov-
ery that frontotemporal dementia is associated with pro-
granulin mutations in some patients (28,29). The clinical
phenotype of progranulin-null mutations includes behav-
ioral abnormalities, language disorders, and Parkinson’s
disease (9). There is no systematic investigation of the
metabolic consequences of mutations in the progranulin
gene. The physiological function of progranulin is com-
plex, with the full-length form of the protein having
trophic and anti-inﬂammatory activity, whereas proteo-
lytic cleavage generates granulin peptides that promote
inﬂammatory activity (9). In the periphery, progranulin
promotes wound healing by increasing the accumulation
of neutrophils, macrophages, and other cells in wounds
(13). We therefore hypothesized that progranulin plays a
role in the association between obesity, type 2 diabetes,
and inﬂammatory response and in macrophage accumula-
tion into adipose tissue in patients with obesity.
We developed an ELISA for the measurement of human
serum progranulin concentrations. Progranulin serum
concentrations are not different in men and women and do
not seem to be age dependent. We found 1.4-fold increased
progranulin concentrations in patients with type 2 diabe-
tes. Moreover, circulating progranulin levels correlate with
BMI, total body fat mass, and visceral fat area, suggesting
that progranulin reﬂects the chronic inﬂammation in obe-
sity. We further found signiﬁcant relationships between
progranulin and A1C, total cholesterol, MCP-1, and high-
sensitive CRP serum concentrations. The association be-
tween progranulin and CRP serum concentrations was
independent of the signiﬁcant relationships with BMI and
A1C, whereas the correlation between progranulin and
MCP-1 serum concentrations was not signiﬁcant after
adjustment for BMI. Our data therefore suggest a close
coregulation between CRP and progranulin serum concen-
tration and demonstrate that progranulin may be a novel
biomarker of the chronic inﬂammatory response in central
obesity and associated disturbances. This is further sup-
ported by the ﬁnding that changes in progranulin levels are
best predicted by changes in CRP serum concentrations
after a 4-week training program. Interestingly, CRP serum
concentrations signiﬁcantly improve after 4 weeks of
training both in patients with IGT and type 2 diabetes (4),
whereas signiﬁcant reduction of progranulin was detect-
able only in the type 2 diabetic patients. We cannot
exclude that the number of subjects in the NGT and IGT
groups was not sufﬁcient to detect signiﬁcant changes of
progranulin serum concentrations. The time course of
progranulin serum concentration in response to acute and
chronic exercise created a paradox. Progranulin serum
concentrations increased immediately after exercise fol-
lowed by a signiﬁcant decrease 48 h after the exercise.
Exercise is known to induce an increase in circulating
cytokines (30). Exercise-induced increase in circulating
progranulin could be a consequence of an immune re-
sponse due to local damage in the working muscles. The
exercise-induced progranulin time course is similar to the
effect of acute exercise on plasma IL-6 (30), suggesting
common exercise-related mechanisms for IL-6 and pro-
granulin. Further studies are necessary to investigate
whether increased progranulin serum concentrations are
the cause or consequence of increased IL-6 in response to
exercise.
Another key ﬁnding of our study was the identiﬁcation
of the signiﬁcant relationship between progranulin serum
concentrations and the amount of macrophages within
adipose tissue, especially in the visceral depot. We and
TABLE 3
Univariate correlations between progranulin mRNA expres-
sion in visceral and subcutaneous adipose tissue and mea-
sures of obesity, insulin sensitivity, and parameters of
inﬂammation (n  55)
Adjusted for
BMI
rP value rP value
Visceral progranulin mRNA
Serum progranulin 0.27 0.01 0.17 0.03
CRP 0.25 0.01 0.18 0.02
MCP-1 0.18 0.03 0.06 0.6
Visceral fat area 0.46 0.001 0.28 0.01
BMI 0.41 0.01 — —
Body fat (%) 0.39 0.01 0.04 0.7
Visceral macrophage
number 0.62 0.001 0.45 0.001
HDL cholesterol 0.35 0.001 0.12 0.1
GIR 0.31 0.01 0.11 0.1
Subcutaneous progranulin
mRNA
Subcutaneous
macrophage number 0.6 0.001 0.38 0.001
CRP 0.34 0.001 0.22 0.01
GIR, glucose infusion rate during the steady state of a euglycemic-
hyperinsulinemic clamp.
B.-S. YOUN AND ASSOCIATES
DIABETES, VOL. 58, MARCH 2009 633others have previously shown that macrophage inﬁltration
into adipose tissue accompanies obesity, with a potential
preferential inﬁltration into visceral (omental) compared
with subcutaneous fat (17,18). However, the mechanisms
for macrophage attraction and the higher recruitment of
macrophages in omental than in subcutaneous adipose
tissue are not fully understood. In animal models of
obesity, a relationship has been shown between adipose
cell size and the amount of macrophages in the stroma
vascular fraction of white adipose tissue (WAT) (31).
Cancello et al. (17) suggested that in addition to adipose
cell hypertrophy, depot-speciﬁc vascularization and/or in-
nervation might explain distinct WAT inﬁltration with
immune cells. So far MCP-1 has been suggested as a
circulating factor attracting macrophages in adipose tissue
(16,19). The close association between circulating pro-
granulin and macrophage inﬁltration into adipose tissue
suggests progranulin as a novel chemoattractant protein
recruiting monocytes into adipose tissue. Immunohisto-
chemistry and expression studies revealed that both adi-
pocytes and cells of the SVF of adipose tissue contribute
to progranulin expression in adipose tissue. Our data
therefore suggest that progranulin contributes to the
cross-talk between adipocytes and macrophages in adi-
pose tissue. Increased expression of progranulin in vis-
ceral fat could therefore represent a dysfunction of
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FIG. 4. Chemotactic activity exerted by recombinant human progranulin. A: Erk activation by recombinant human progranulin in MCF10A cells.
To examine the signal of phospho-p44/42 MAPK and p44/42 MAPK, after serum starvation for 24 h, MCF10A cells were stimulated with 500 ng/ml
progranulin. Cell lysates were prepared at different time points as indicated and subjected to Western blot. B: Similar results have been obtained
after treatment of THP-1 with 100 ng/ml progranulin. C: Transwell migration assay using THP-1 cells was conducted as described in RESEARCH
DESIGN AND METHODS. THP-1 cells were placed into upper chambers, setting out to cell migration to lower chambers harboring no progranulin,
different concentrations of progranulin (10, 100, and 250 ng/ml), or boiled progranulin. After 16 h, migrated cells were counted. D: Chemotactic
effect of human Progranulin-FLAG in THP-1 cells. Cell migration of THP-1 monocytic leukemia cells was evaluated in disposable 24-well transwell
polystyrene membrane with 8-m pore size. hProgranulin-FLAG (100 ng/ml) was diluted in RPMI 1640 supplemented with 0.5% FBS and was then
added to the low chamber. 0, 10, 50, 100, and 250 ng/ml hProgranulin were added into upper chamber together with THP-1 cells (2  10
5 cells per
well). After 16-h incubation at 37°C in 5% CO2 humidiﬁed atmosphere, migration cells in the lower chamber were counted. Migrated cells in two
separate ﬁelds per well from duplicate wells were enumerated on a hemacytometer by means of light microscopy. UC, upper chamber; LC, lower
chamber. E and F: Transwell migration assay comparing human progranulin (hPrgn) and human MCP-1 (hMCP-1) using PTX-treated or
PD98059-treated THP-1 cells.
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ously recognized increased macrophage numbers in omen-
tal depots (17,18). Although human adipose tissue
macrophages have been shown to have an anti-inﬂamma-
tory phenotype, they are capable of excessive proinﬂam-
matory mediator production (32). Macrophage-secreted
factors, including TNF- and IL-1, have been shown to
induce adipocyte inﬂammatory response to a greater
extent than the levels achieved by individual macro-
phage cytokines (33). Here, we identiﬁed progranulin as
an additional secreted factor from both macrophages
and adipocytes, which could induce or promote adipo-
cyte inﬂammatory response and recruit monocytes into
adipose tissue. We could demonstrate that in vitro
chemotactic activity of progranulin using a human mac-
rophage-like cell line, THP-1 cells, is indistinguishable
from the so far best-established marker of adipose
macrophage inﬁltration, MCP-1 (34). These data further
support our hypothesis that progranulin represents a
previously unrecognized chemoattractant molecule,
which contributes to the higher number of adipose
tissue macrophages in patients with central obesity.
Similar to the previously reported higher MCP-1 release
from visceral compared with subcutaneous fat depot
(35), our observation of higher progranulin expression
in visceral adipose tissue could contribute to predomi-
nant omental macrophage inﬁltration in human visceral
obesity. However, unlike MCP-1, our data strongly sug-
gest that progranulin-mediated chemotaxis depends on
Erk, but not on G, indicating that progranulin recep-
tor(s), if any, may not be a G-protein–coupled recep-
tor(s). Because of heterogeneity of tissue macrophages,
including the obesity-induced omentum-macrophages, a
potential contribution of progranulin to recruitment or
activation of macrophages remains to be determined.
This should also require identiﬁcation of the cell surface
markers speciﬁcally expressed in the omental macro-
phages. Nevertheless, progranulin could be an impor-
tant homing factor for the omental macrophages.
In conclusion, our data suggest progranulin as a novel
marker for chronic inﬂammation associated with visceral
obesity and type 2 diabetes in humans. In addition, pro-
granulin plays a role as a chemoattractant molecule,
which, similar to MCP-1, could contribute to increased
macrophage inﬁltration in omental adipose tissue of pa-
tients with predominantly visceral obesity.
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